EARNEST试验144周随访:洛匹那韦联合NRTI、联合拉替拉韦或单药治疗HIV的二线方案比较
EARNEST随机对照试验在撒哈拉以南非洲5国14个中心纳入1277例对非核苷类逆转录酶抑制剂一线方案应答不佳的HIV感染者,比较洛匹那韦联合NRTI、联合拉替拉韦或单药治疗144周的疗效与安全性。结果显示联合拉替拉韦未达到非劣效标准,单药治疗劣于联合NRTI,联合NRTI仍是资源有限地区最佳标准化二线方案。
要点
- 洛匹那韦联合拉替拉韦在144周病毒学疗效上未达到非劣效标准。
- 洛匹那韦单药治疗病毒学抑制率显著低于联合NRTI方案。
- 三组间严重不良事件及3/4级不良事件无差异。
核心结论
- 洛匹那韦联合拉替拉韦在病毒学疗效或安全性上未优于洛匹那韦联合NRTI。
- 洛匹那韦联合拉替拉韦在主要分析中未达到非劣效标准。
- 洛匹那韦联合NRTI仍是资源有限地区最佳标准化二线方案。
研究设计与样本
- EARNEST为随机对照试验,在撒哈拉以南非洲5国14个中心进行。
- 纳入1277例对非核苷类逆转录酶抑制剂一线方案应答不佳的HIV感染成人或青少年。
- 随机分为洛匹那韦联合NRTI组、联合拉替拉韦组或洛匹那韦单药组。
主要发现
- 144周时洛匹那韦联合NRTI组367例中317例(86%)病毒载量<400 copies/mL。
- 三组间严重不良事件、3/4级不良事件(总体或ART相关)及导致治疗修改的事件无差异。
关键数值与推荐
- 非劣效界值为10%。
临床怎么用
- 在资源有限地区,HIV二线治疗仍应优先选择洛匹那韦联合两种NRTI的标准方案。
- 不建议采用洛匹那韦联合拉替拉韦或洛匹那韦单药作为常规二线方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in typical programme settings. METHODS: We analysed the 144-week outcomes at the completion of the EARNEST trial, a randomised controlled trial done in HIV-infected adults or adolescents in 14 sites in five sub-Saharan African countries (Uganda, Zimbabwe, Malawi, Kenya, Zambia). Participants were those who were no longer responding to non-NRTI-based first-line ART, as assessed with WHO criteria, confirmed by viral-load testing. Participants were randomly assigned to receive a ritonavir-boosted protease inhibitor (lopinavir 400 mg with ritonavir 100 mg, twice per day) plus two or three clinician-selected NRTIs (protease inhibitor plus NRTI group), protease inhibitor plus raltegravir (400 mg twice per day; protease inhibitor plus raltegravir group), or protease inhibitor monotherapy (plus raltegravir induction for first 12 weeks, re-intensified to combination therapy after week 96; protease inhibitor monotherapy group). Randomisation was by computer-generated randomisation sequence, with variable block size. The primary outcome was viral load of less than 400 copies per mL at week 144, for which we assessed non-inferiority with a one-sided α of 0·025, and superiority with a two-sided α of 0·025. The EARNEST trial is registered with ISRCTN, number 37737787. FINDINGS: Between April 12, 2010, and April 29, 2011, 1837 patients were screened for eligibility, of whom 1277 patients were randomly assigned to an intervention group. In the primary (complete-case) analysis at 144 weeks, 317 (86%) of 367 in the protease inhibitor plus NRTI group had viral loads of less than 400 copies per mL compared with 312 (81%) of 383 in the protease inhibitor plus raltegravir group (p=0·07; lower 95% confidence limit for difference 10·2% vs specified non-inferiority margin 10%). In the protease inhibitor monotherapy group, 292 (78%) of 375 had viral loads of less than 400 copies per mL; p=0·003 versus the protease inhibitor plus NRTI group at 144 weeks. There was no difference between groups in serious adverse events, grade 3 or 4 adverse events (total or ART-related), or events that resulted in treatment modification. INTERPRETATION: Protease inhibitor plus raltegravir offered no advantage over protease inhibitor plus NRTI in virological efficacy or safety. In the primary analysis, protease inhibitor plus raltegravir did not meet non-inferiority criteria. A regimen of protease inhibitor with NRTIs remains the best standardised second-line regimen for use in programmes in resource-limited settings. FUNDING: European and Developing Countries Clinical Trials Partnership (EDCTP), UK Medical Research Council, Instituto de Salud Carlos III, Irish Aid, Swedish International Development Cooperation Agency, Instituto Superiore di Sanita, Merck, ViiV Healthcare, WHO.
引用
- Hakim JG, Thompson J, Kityo C, et al. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Lancet Infect Dis. 2017. PMID: 29108797. doi:10.1016/S1473-3099(17)30630-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。